Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its CEO Ivor Elrifi bought 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market.
This brings his current purchased shares total to 193,848.
The biotech firm is advancing intranasal foralumab, its lead candidate and the first fully human anti-CD3 monoclonal antibody, for breakthrough immunomodulation therapies.